Source - RNS
RNS Number : 4660Z
Advanced Medical Solutions Grp PLC
31 August 2018
 

31 August 2018

 

Advanced Medical Solutions Group plc

("AMS" or the "Company" or the "Group")

 

Application for Admission

 

Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that an application has been made to the London Stock Exchange for the admission of a total of 8,023,268 ordinary shares of 5 pence each (the "Ordinary Shares") to trading on AIM.

 

All of the Ordinary Shares to which this application relates, have been previously issued and allotted under various employee share schemes. As a result, following the admission of these Ordinary Shares, there will be no change to the Company's current issued share capital, which consists of 213,442,312 Ordinary Shares with voting rights.

 

Further, AMS announces that an application has been made to the London Stock Exchange for the block listing of securities in respect of a total of 4,476,264 ordinary shares of 5 pence each (the "New Ordinary Shares") to be admitted to trading on AIM.

 

The block listing application relates to New Ordinary Shares to be issued from time to time pursuant to the exercise of share options under the Company's existing schemes as follows:

 

Scheme

No. of New Ordinary Shares

Deferred Share Bonus Scheme

804,569

Enterprise Management Incentive Scheme

43,172

Company Share Option Plan

439,808

Unapproved Executive Share Option Scheme

1,477,329

Long Term Incentive Plan

1,224,399

Deferred Annual Bonus Scheme

486,987

 

When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of 5 pence each in the capital of Advanced Medical Solutions Group plc.

 

It is expected that admission will become effective for the Ordinary Shares on 6 September 2018.

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Chief Financial Officer

 




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser

[email protected] 

 



Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Daniel Adams / Patrick Robb / Gary Clarence


 

About Advanced Medical Solutions Group plc - see www.admedsol.com 

 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

 

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees.  For more information, please see www.admedsol.com.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ALSBUGDIXGXBGIB